Patents by Inventor Alain Moussy

Alain Moussy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10570122
    Abstract: The present invention relates to compounds of general formula (I). wherein A represents an optionally substituted heterocycle group, B represents an aryl or heteroaryl group and wherein X, R1, R2, R3, R4 and R5 are as defined in the description. Compounds of formula (I) are useful to destroy, inhibit, or prevent the growth or spread of cells, especially malignant cells, into surrounding tissues implicated in a variety of human and animal diseases.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: February 25, 2020
    Assignee: AB Science
    Inventors: Alain Moussy, Abdellah Benjahad, Didier Pez, Franck Sandrinelli, Jason Martin, Willy Picoul, Emmanuel Chevenier
  • Patent number: 10392373
    Abstract: The present invention is concerned with substituted oxazole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, autoimmune, allergic, hematological, inflammatory and degenerative disorders. In particular, the compounds of the invention are Syk inhibitors. The invention also relates to a process for manufacturing the compounds of the invention.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: August 27, 2019
    Assignee: AB Science
    Inventors: Alain Moussy, Abdellah Benjahad, Didier Pez, Claire Schalon, Franck Sandrinelli, Jason Martin, Willy Picoul, Emmanuel Chevenier
  • Patent number: 10238649
    Abstract: A method for treating patients afflicted with cancer, wherein the patients are treated with a compound including tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one antineoplastic agent. The tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, and the optional at least one antineoplastic agent, are administered in a dosage regimen that includes a therapeutically effective amount. Also described are methods for predicting therapeutic response to the treatment in a given patient and therefore identification of applicable patient subpopulations based upon these predictor factors; sometimes referred to as biomarkers. One method is based upon the clinical marker of pain intensity.
    Type: Grant
    Filed: October 4, 2013
    Date of Patent: March 26, 2019
    Assignee: AB SCIENCE
    Inventors: Alain Moussy, Jean-Pierre Kinet
  • Publication number: 20190055230
    Abstract: The present invention is concerned with substituted oxazole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, autoimmune, allergic, hematological, inflammatory and degenerative disorders. In particular, the compounds of the invention are Syk inhibitors. The invention also relates to a process for manufacturing the compounds of the invention.
    Type: Application
    Filed: September 16, 2016
    Publication date: February 21, 2019
    Inventors: Alain Moussy, Abdellah Benjahad, Didier Pez, Claire Schalon, Franck Sandrinelli, Jason Martin, Willy Picoul, Emmanuel Chevenier
  • Patent number: 10202370
    Abstract: Disclosed are compounds of formula I or pharmaceutically acceptable salts thereof: Wherein n, R1, R2, R3, R4, R5, A, Q and X are as defined in the description. These compounds selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective native and/or mutant c-kit inhibitors.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: February 12, 2019
    Assignee: AB SCIENCE
    Inventors: Alain Moussy, Abdellah Benjahad, Claire Schalon, Didier Pez, Emmanuel Chevenier, Franck Sandrinelli, Jason Martin, Willy Picoul
  • Publication number: 20180311236
    Abstract: Disclosed is a mast cell inhibitor, a pharmaceutical composition and a method for the treatment of patients afflicted with Parkinson's disease, wherein the patients are treated with a tyrosine kinase inhibitor or mast cell inhibitor, in particular masitinib, or a compound selected from imatinib, cromolyn sodium, midostaurin, BLU-285, bosutinib, ibrutinib, LAS189386, DP-2618, fostamatinib, dasatinib, sunitinib, axitinib, pazopanib, and toceranib or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient.
    Type: Application
    Filed: October 28, 2016
    Publication date: November 1, 2018
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Patent number: 10092564
    Abstract: Disclosed is a method for treating patients afflicted with non-aggressive or moderately aggressive amyotrophic lateral sclerosis (ALS) whose rate of change of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) prior to treatment initiation is <1.1 points per month, the method including administering a tyrosine kinase inhibitor or mast cell inhibitor, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: October 9, 2018
    Assignee: AB SCIENCE
    Inventors: Alain Moussy, Jean-Pierre Kinet, Colin Mansfield
  • Patent number: 10053455
    Abstract: The present invention is concerned with substituted oxazole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, autoimmune, allergic, and degenerative disorders. In particular, the presently disclosed compounds are Syk inhibitors.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: August 21, 2018
    Assignee: AB SCIENCE
    Inventors: Abdellah Benjahad, Jason Martin, Claire Schalon, Didier Pez, Emmanuel Chevenier, Franck Sandrinelli, Willy Picoul, Alain Moussy
  • Patent number: 10045978
    Abstract: The treatment of mastocytosis, and in particular indolent forms of mastocytosis (including smoldering systemic, indolent systemic and cutaneous mastocytosis), including the administration of a tyrosine kinase inhibitor or a mast cell inhibitor, especially masitinib or a pharmaceutically acceptable salt or solvate thereof, in particular in an appropriate dosage regimen.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: August 14, 2018
    Assignee: AB SCIENCE
    Inventors: Alain Moussy, Jean-Pierre Kinet
  • Publication number: 20180179195
    Abstract: The present invention is concerned with substituted oxazole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, autoimmune, allergic, and degenerative disorders. In particular, the presently disclosed compounds are Syk inhibitors.
    Type: Application
    Filed: March 23, 2015
    Publication date: June 28, 2018
    Inventors: Abdellah BENJAHAD, Jason MARTIN, Claire SCHALON, Didier PEZ, Emmanuel CHEVENIER, Franck SANDRINELLI, Willy PICOUL, Alain MOUSSY
  • Publication number: 20180117037
    Abstract: Disclosed is a method for treating patients afflicted with non-aggressive or moderately aggressive amyotrophic lateral sclerosis (ALS) whose rate of change of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) prior to treatment initiation is <1.1 points per month, the method including administering a tyrosine kinase inhibitor or mast cell inhibitor, in particular masitinib, or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient.
    Type: Application
    Filed: March 24, 2017
    Publication date: May 3, 2018
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Publication number: 20180079747
    Abstract: The present invention relates to compounds of general formula (I). wherein A represents an optionally substituted heterocycle group, B represents an aryl or heteroaryl group and wherein X, R1, R2, R3, R4 and R5 are as defined in the description.
    Type: Application
    Filed: February 5, 2016
    Publication date: March 22, 2018
    Inventors: Alain Moussy, Abdellah Benjahad, Didier Pez, Franck Sandrinelli, Jason Martin, Willy Picoul, Emmanuel Chevenier
  • Publication number: 20170340629
    Abstract: Disclosed is a method for treating breast cancer in a subject in need thereof, including administering to the subject a therapeutically effective amount of a tyrosine kinase inhibitor or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with a therapeutically effective amount of a chemotherapeutic agent.
    Type: Application
    Filed: December 15, 2015
    Publication date: November 30, 2017
    Applicant: AB SCIENCE
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Publication number: 20170196853
    Abstract: A treatment of patients afflicted with prostate cancer, wherein the treatment includes administering to a mammal in need thereof at least one tyrosine kinase inhibitor or mast cell inhibitor that is an inhibitor of kinase activity selected from the tyrosine kinases of: c-Kit, PDGFR, LYN, FYN, or any combination thereof, in particular masitinib, optionally in combination with at least one pharmaceutically active ingredient.
    Type: Application
    Filed: June 2, 2014
    Publication date: July 13, 2017
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Publication number: 20170119760
    Abstract: A mast cell inhibitor, a pharmaceutical composition and a method for treating patients afflicted with Progressive Supranuclear Palsy (PSP), wherein the patients are treated with a tyrosine kinase inhibitor, c-Kit inhibitor or mast cell inhibitor, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient.
    Type: Application
    Filed: October 28, 2016
    Publication date: May 4, 2017
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Publication number: 20170020867
    Abstract: A method for treating patients afflicted with Crohn's disease, wherein the patients are treated with a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one pharmaceutically active ingredient for treatment of Crohn's disease.
    Type: Application
    Filed: July 21, 2016
    Publication date: January 26, 2017
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Publication number: 20160263110
    Abstract: A treatment of patients afflicted with Amyotrophic Lateral Sclerosis (ALS), wherein the patients are treated with a tyrosine kinase inhibitor, mast cell inhibitor or c-Kit inhibitor, in particular masitinib, optionally in combination with at least one pharmaceutically active ingredient
    Type: Application
    Filed: November 4, 2014
    Publication date: September 15, 2016
    Inventors: Jean Pierre KINET, Alain MOUSSY, Colin MANSFIELD
  • Publication number: 20160244845
    Abstract: An in vitro method for determining the prognosis of pancreatic cancer in a patient includes the following steps: a) measuring the expression level of at least one gene chosen from the group consisting of: ACOX-1, TNFRSF10B, LYN, HIF1A, UBE2H, PARP2, ABCC1, ABCC3, IGJ and RPS23 or homologous genes, in a blood sample of the patient, b) predicting the outcome of the pancreatic cancer in the patient. a kit specifically designed to carry out such a method is also described.
    Type: Application
    Filed: October 3, 2014
    Publication date: August 25, 2016
    Applicants: AB Science, ACOBIOM
    Inventors: David PIQUEMAL, Alain MOUSSY, Jean-Pierre KINET
  • Publication number: 20160175302
    Abstract: The present invention relates to a method for treating gastric cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a tyrosine kinase inhibitor, in combination with a therapeutically effective amount of a chemotherapeutic agent.
    Type: Application
    Filed: December 17, 2015
    Publication date: June 23, 2016
    Inventors: Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
  • Publication number: 20160152608
    Abstract: Disclosed are compounds of formula I or pharmaceutically acceptable salts thereof: Wherein n, R1, R2, R3, R4, R5, A, Q and X are as defined in the description. These compounds selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective native and/or mutant c-kit inhibitors.
    Type: Application
    Filed: June 20, 2014
    Publication date: June 2, 2016
    Inventors: Alain MOUSSY, Abdellah BENJAHAD, Claire SCHALON, Didier PEZ, Emmanuel CHEVENIER, Franck SANDRINELLI, Jason MARTIN, Willy PICOUL